Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 25, 2015 1:36 PM ET

Biotechnology

Company Overview of Pulmatrix, Inc.

Company Overview

Pulmatrix, Inc. is a clinical stage biotechnology company. It focuses on developing therapies for the treatment of chronic respiratory diseases, including cystic fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company develops iSPERSE (inhaled small particles easily respirable and emitted), a drug delivery platform that enables drugs to be delivered in inhaled dry powders; and uses particle engineering to create dry powder formulations with various drug substances, such as small molecules, biologics, and multi-drug combinations. Its product pipeline includes PUR0200, a once daily inhaled bronchodilator for chronic obstructive pulmonary disease; and PUR...

99 Hayden Avenue

Suite 390

Lexington, MA 02421

United States

Founded in 2003

Phone:

781-357-2333

Fax:

781-357-2399

Key Executives for Pulmatrix, Inc.

Chief Executive Officer and Director
Co-Founder and Chairman of the Scientific Advisory Board
Age: 66
Co-Founder, Director and Member of the Scientific Advisory Board
Age: 53
Co-Founder
Age: 64
Chief Medical Officer and Senior Vice President
Compensation as of Fiscal Year 2014.

Pulmatrix, Inc. Key Developments

Ruthigen, Inc. and Pulmatrix, Inc. Appoint Robert Clarke as President and CEO

Ruthigen agreed to acquire Pulmatrix. Upon completion of the merger, Ruthigen will be renamed Pulmatrix. Pulmatrix President and CEO Robert Clarke will be appointed as the president and CEO of the combined company.

Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015

Pulmatrix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

Pulmatrix, Inc. Announces Positive Results from Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients

Pulmatrix, Inc. announced the completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product from the company's novel iSPERSE™ inhaled dry powder technology. The first part of the Phase 1B clinical trial evaluated the safety, tolerability and the pharmacokinetic/pharmacodynamic profile of single ascending doses of PUR0200 in patients with moderate COPD. The first part of the Phase 1B study evaluated pharmacokinetics and pulmonary function after administration of four single ascending doses of PUR0200 in 24 patients with moderate COPD. All doses of PUR0200 were generally well tolerated and were associated with increases in lung function, as measured by peak and trough forced expiratory volume (FEV1) from baseline, and compared to placebo dosing. Pharmacokinetic assessments affirmed the effective lung delivery of PUR0200 and the iSPERSE platform and compared favorably to published data on lactose blend formulations. The data from the first part of the study will be used to inform dose selection for the second part of the study, a cross-over design study that starts this month and includes an active comparator arm. The study is targeted for completion in the first quarter of 2014 and data from both parts of the study will be presented at a future scientific meeting.

Similar Private Companies By Industry

Company Name Region
Acclaim Biotechnology United States
Apollo Biosciences, Inc. United States
Cambrex Bio Science Baltimore, Inc. United States
Tolero Pharmaceuticals, Inc. United States
Ecopesticides International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 13, 2015
--
Merger/Acquisition
March 13, 2015
Ruthigen, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pulmatrix, Inc., please visit www.pulmatrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.